The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…

UnitedHealth Group

'Big 3' insurer Anthem refuses to cover Sarepta's controversial DMD med Exondys 51

UPDATED: UnitedHealth adds to formulary pain for Sanofi, Amgen and Novartis